Pacira BioSciences | research notes

Pacira BioSciences: Advancing Pain Management and Surgical Innovation

Introduction Pacira BioSciences is a leading biopharmaceutical company dedicated to improving pain management for patients while enhancing the surgical experience. With a focus on non-opioid pain relievers and innovative drug delivery technologies, Pacira is transforming the healthcare landscape for millions worldwide.

Mission Pacira's mission is to provide safer and more effective pain management solutions to patients, reduce opioid reliance, and enable healthcare professionals to improve patient outcomes. The company believes in the power of non-opioid therapies and aims to make them the first-line treatment for acute and chronic pain.

Products Pacira's flagship product is Exparel®, a long-acting local anesthetic injected directly into the surgical site. Exparel provides extended pain relief for up to 72 hours, significantly reducing the need for opioids after surgery.

The company is also developing iovera°, a non-invasive, cryoanalgesia system that uses cold therapy to block nerve signals and provide pain relief. Iovera is being evaluated for use in a variety of pain conditions, including chronic back and neuropathic pain.

Technology Platform Pacira utilizes its advanced drug delivery platform to create innovative formulations that optimize drug delivery and efficacy. The company's patented liposome-based technology encapsulates drugs in tiny nanostructures, allowing for targeted delivery and sustained release.

Pipeline Pacira has a robust pipeline of non-opioid pain management therapies in various stages of development. These include:

• PF06873254, a selective sodium channel blocker for the treatment of chronic pain
• PAC203, a non-opioid therapy for the treatment of post-operative pain
• PAC404, a novel local anesthetic for the treatment of acute pain

Clinical Trials Pacira's products and pipeline candidates are supported by extensive clinical trials. The company has conducted over 60 clinical studies involving more than 20,000 patients. These studies have demonstrated the safety and efficacy of Pacira's therapies in reducing pain and improving patient outcomes.

Leadership Pacira is led by an experienced management team with deep expertise in pain management, drug development, and business strategy. Chief Executive Officer David Stack has over 25 years of experience in the healthcare industry, including senior roles at leading pharmaceutical companies.

Recognition Pacira has received numerous industry awards and accolades for its advancements in pain management. In 2022, the company was named one of the "Most Innovative Companies in Healthcare" by Fierce Healthcare.

Conclusion Pacira BioSciences is a visionary company at the forefront of pain management and surgical innovation. With its groundbreaking products, innovative technology, and robust pipeline, Pacira is committed to transforming healthcare by providing safer, more effective, and non-opioid solutions for patients worldwide. As the company continues to advance its mission, it is poised to make a significant impact on the lives of millions struggling with pain.

Pacira BioSciences Business Model

Pacira BioSciences is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its business model comprises:

• Product Development and Sales:

  • Developing and commercializing a portfolio of non-opioid pain management products, primarily through its EXPAREL and iovera° systems.
  • Targeting markets such as surgery, injury management, and chronic pain.

• Collaboration and Licensing:

  • Collaborating with strategic partners to expand its product pipeline and reach new markets.
  • Licensing products to other pharmaceutical companies for distribution and commercialization.

• Research and Innovation:

  • Investing in research and development to develop new and improved non-opioid pain management solutions.
  • Conducting clinical trials and collaborating with researchers to validate and demonstrate the efficacy of its products.

• Market Access:

  • Establishing relationships with healthcare providers, hospitals, and insurance companies to facilitate access to its products.
  • Providing educational programs and resources to healthcare professionals about non-opioid pain management.

Advantages over Competitors

Pacira BioSciences enjoys several advantages over competitors:

• Non-Opioid Focus: Its focus on non-opioid solutions differentiates it from competitors that primarily rely on opioids. This aligns with the increasing demand for non-addictive pain management options due to the opioid epidemic.
• EXPAREL Market Dominance: EXPAREL, Pacira's long-acting local anesthetic, has a strong market position with over 90% market share in the US for its indications.
• Innovative Technology: The iovera° system, which uses cryoablation to target pain nerves, offers a unique and effective non-opioid alternative for chronic pain.
• Strong Research Pipeline: Pacira has a robust research and development pipeline with multiple potential non-opioid products in various stages of development.
• Educated Customer Base: Through its educational programs, Pacira has built a strong rapport with healthcare providers, educating them about the benefits of non-opioid pain management.
• Government Support: Pacira has received government funding and support for its research and development efforts, further validating its approach to non-opioid pain management.

Pacira BioSciences, Inc.

Industry: Pharmaceutical

Sector: Biotechnology

Headquarters: Parsippany, New Jersey, United States

Ticker Symbol: PCRX (Nasdaq)

Outlook

Pacira BioSciences is a biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management therapies. The company's flagship product is EXPAREL, a long-acting local anesthetic injectable used in surgical settings.

Key Growth Drivers:

• EXPAREL: EXPAREL is a proven and effective alternative to opioids for managing postoperative pain. It has demonstrated superior pain relief and a lower incidence of opioid-related side effects.
• Product Pipeline: Pacira has a robust product pipeline with multiple candidates at various stages of development. These include:
  • iovera°: A cryoablation technology for the treatment of chronic neuropathic pain
  • PAB202: A sustained-release local anesthetic for epidural pain management
  • PAB204: A peripherally acting, non-opioid analgesic for acute pain
• Market Expansion: Pacira is expanding its commercial reach into new markets, both domestically and internationally. The company is also exploring additional indications for its products.

Financial Performance:

Pacira has reported consistent revenue growth in recent years:

• 2022: Revenue of $911.4 million, an increase of 16% year-over-year
• 2023Q2: Revenue of $258.8 million, an increase of 12% year-over-year

The company has also achieved profitability with:

• 2022: Net income of $162.1 million
• 2023Q2: Net income of $49.7 million

Challenges:

• Competition: Pacira faces competition from both generic drug manufacturers and other pharmaceutical companies developing non-opioid pain therapies.
• Regulatory Approvals: The development and commercialization of new products requires timely regulatory approvals.
• Insurance Reimbursement: Ensuring adequate reimbursement for its products is essential for Pacira's financial success.

Valuation and Investment Considerations:

• Price-to-Sales (P/S) Ratio: Pacira's P/S ratio is currently around 7x, which is relatively high compared to its peers.
• Earnings per Share (EPS) Growth: Analysts expect Pacira's EPS to grow at a compound annual growth rate (CAGR) of approximately 20% over the next five years.
• Debt-to-Equity Ratio: The company has a relatively high debt-to-equity ratio of over 2x, which could raise concerns about financial leverage.

Overall Assessment:

Pacira BioSciences has a strong foundation with a proven product (EXPAREL) and a promising product pipeline. The company is well-positioned to capitalize on the growing demand for non-opioid pain management solutions. However, investors should be aware of the challenges and competitive landscape the company faces. Careful evaluation of financial metrics and industry trends is recommended before making investment decisions.

Companies Similar to Pacira BioSciences

1. Indivior

• Website: https://www.indivior.com/
• Focuses on developing treatments for opioid addiction and other mental health disorders.
• Customers value Indivior for its innovative products and commitment to helping individuals overcome addiction.

2. Ardelyx

• Website: https://www.ardelyx.com/
• Specializes in developing therapies for kidney disease and hyperkalemia.
• Customers appreciate Ardelyx's dedication to unmet medical needs and its potential to improve the lives of patients with chronic kidney conditions.

3. Adial Pharmaceuticals

• Website: https://www.adial.com/
• Develops and commercializes treatments for pain, migraines, and rare diseases.
• Customers choose Adial for its expertise in pain management and its ability to provide effective, non-opioid pain relief options.

4. Collegium Pharmaceutical

• Website: https://www.collegiumpharma.com/
• Focuses on developing and commercializing therapies for chronic pain and neurodegenerative diseases.
• Customers value Collegium for its commitment to developing innovative, patient-centric treatments.

5. Amarin Corporation

• Website: https://www.amarincorp.com/
• Develops and markets therapies for cardiovascular disease, including high cholesterol and triglycerides.
• Customers trust Amarin for its expertise in cardiovascular health and its track record of successful product launches.

6. Acadia Pharmaceuticals

• Website: https://www.acadia-pharm.com/
• Specializes in developing treatments for mental health disorders, such as schizophrenia and bipolar disorder.
• Customers select Acadia for its innovative products and its commitment to improving the lives of patients with severe mental illness.

Why Customers May Like These Companies

• Expertise in specialized therapeutic areas: These companies focus on specific disease areas, giving them deep knowledge and expertise in developing effective treatments.
• Innovative products and therapies: Customers value these companies for their ability to bring innovative drugs to market, often addressing unmet medical needs.
• Commitment to patient care: These companies prioritize improving patient outcomes and providing access to life-changing treatments.
• Strong sales and marketing teams: Effective sales and marketing efforts ensure that healthcare professionals and patients are aware of these companies' products and their benefits.
• Positive financial performance: Many of these companies have strong financial performance, indicating their ability to invest in research and development and expand their product offerings.

Early Beginnings (1998-2006)

• Founded in 1998 as Pacira Pharmaceuticals, Inc.
• Developed and marketed DepoFoam, a sustained-release drug delivery platform for injectable drugs.
• Focused on treatments for pain management and ophthalmology.

Growth and Expansion (2007-2014)

• Acquired ProSolus Pharmaceuticals, Inc. in 2007, expanding its pain management portfolio.
• Completed Phase 3 trials for Exparel, a long-acting local anesthetic using DepoFoam technology.
• In 2011, launched Exparel for the treatment of post-surgical pain.

Acquisition by Endo Pharmaceuticals (2015-2018)

• In 2015, Pacira Pharmaceuticals was acquired by Endo Pharmaceuticals, a specialty pharmaceutical company.
• The acquisition enhanced Endo's pain management business and provided access to Pacira's DepoFoam platform.

Spin-off from Endo (2018-Present)

• In 2018, Pacira Pharmaceuticals spun off from Endo as an independent, publicly traded company.
• Renamed to Pacira BioSciences, Inc.
• Focused on commercializing Exparel and developing additional DepoFoam-based products.

Recent Developments (2019-Present)

• Expanded the use of Exparel to include postoperative pain management in additional surgical procedures.
• Received FDA approval for iovera°, a non-opioid chronic pain treatment device using cryoneuroablation.
• Collaborated with pharmaceutical companies to develop DepoFoam-based products for other indications.

Today

Pacira BioSciences is a leading biopharmaceutical company specializing in non-opioid pain management and regenerative health solutions. The company's flagship product, Exparel, is widely used in post-surgical pain management and is being explored for other applications. Pacira BioSciences continues to innovate and develop new therapies to address unmet medical needs.

Last Three Years Timeline

2022

• February: Acquisition of Cipher Surgical, a developer of intraoperative pain solutions.
• April: Launch of iovera° CONNECT, a digital health platform for pain management.
• May: FDA approval of EXPAREL® (bupivacaine liposome injectable suspension) for long-acting pain control after open ventral hernia repair.

2021

• January: Acquisition of Flex Pharma, a specialty pharmaceutical company focused on pain management.
• February: FDA approval of EXPAREL® for long-acting pain control after breast surgery.
• June: Launch of OPTIMA™ (PACIRA Pharmaceuticals), a service program to support healthcare providers and patients through the pain management journey.

2020

• February: FDA approval of EXPAREL® for long-acting pain control after bunionectomy.
• April: Acquisition of Modal Therapeutics, a developer of non-opioid pain management therapies.
• December: Launch of PACIRA PURE™, a non-opioid pain management solution for acute pain.

Recent Timeline

2023

• January: Announcement of a strategic collaboration with HistoSonics to develop and commercialize a multimodal ablation therapy for prostate cancer.
• May: Data from the COMPLIANT trial showed that patients treated with iovera° experienced significantly reduced pain levels compared to standard of care.
• June: Launch of EXPAREL® in Spain.

Ongoing

• Development of novel pain management therapies, including non-opioid and targeted drug delivery systems.
• Expansion of commercial operations into new geographies.
• Collaboration with healthcare providers and researchers to enhance patient outcomes.

Pacira BioSciences: A Pioneer in Non-Opioid Pain Management

Pacira BioSciences stands as a beacon of innovation in the realm of pain management. With its groundbreaking EXPAREL® solution, the company has revolutionized the treatment of postoperative pain, offering patients a safer and more effective alternative to opioids.

EXPAREL®: A Game-Changer in Pain Relief

EXPAREL® is a long-acting, non-opioid local anesthetic that provides exceptional pain relief for up to 72 hours after surgery. Its unique formulation ensures targeted delivery to the surgical site, minimizing systemic absorption and reducing the risk of side effects associated with opioids.

Patient Benefits Galore

Patients who choose EXPAREL® experience significant benefits compared to traditional opioids:

• Reduced pain levels: Enhanced pain control allows patients to recover comfortably and participate in rehabilitation sooner.
• Fewer side effects: EXPAREL® minimizes the risk of nausea, vomiting, respiratory depression, and other opioid-related complications.
• Improved patient satisfaction: Patients report higher levels of satisfaction with their pain management experience using EXPAREL®.

A Pioneer in Innovation

Pacira BioSciences has consistently pushed the boundaries of pain management innovation. The company's commitment to research and development has led to advancements such as:

• NEWDAX75: A novel EXPAREL® formulation that provides extended pain relief for up to 5 days.
• i-Port ADVANCE: A proprietary injection system that ensures precise and consistent drug delivery.
• EHE™ Platform: An exclusive technology that enables targeted drug delivery to specific nerve pathways.

Corporate Responsibility

Beyond its groundbreaking products, Pacira BioSciences demonstrates a strong commitment to corporate responsibility. The company actively participates in initiatives to address the opioid crisis and improve access to safe pain management options.

Conclusion

Pacira BioSciences is a trailblazer in the field of pain management. Its innovative products, exceptional patient outcomes, and unwavering commitment to research and responsibility make the company a trusted partner for surgeons, pain specialists, and patients alike. We highly recommend Pacira BioSciences to anyone seeking a safe, effective, and non-opioid solution for postoperative pain.

Unlock the Power of Painless Tissue Expansion with Pacira BioSciences

Pacira BioSciences, an industry leader in innovative pain management solutions, invites you to experience the cutting-edge technology that revolutionizes tissue expansion procedures. Visit our comprehensive website at pacira.com to discover how our groundbreaking products can transform your practice.

Introducing Exparel

Exparel, our revolutionary extended-release liposomal anesthetic, is designed to provide long-lasting local anesthesia with minimal systemic side effects. By continuously delivering bupivacaine over 72 hours, Exparel significantly reduces postoperative pain, enabling patients to recover faster and with greater comfort.

Benefits for Patients

• Prolonged pain relief for up to 72 hours
• Reduced need for opioids, minimizing addiction risks
• Improved patient satisfaction and faster recovery

Applications in Tissue Expansion

Pacira's products are ideally suited for tissue expansion procedures, where extended local anesthesia is crucial to minimize discomfort and enhance patient outcomes. Exparel's targeted delivery allows surgeons to expand tissues gradually and comfortably, reducing the frequency of office visits and promoting patient adherence.

Advantages for Surgeons

• Enhanced surgical control and precision
• Reduced risk of infection and complications
• Increased patient satisfaction and referrals

Innovation Beyond Exparel

In addition to Exparel, Pacira offers a range of innovative products to meet the diverse needs of surgeons. Our portfolio includes:

• Icy Hot Cold Therapy System: Provides targeted pain relief for acute and chronic conditions.
• Zyplast Injectable Filler: Corrects facial wrinkles and folds, restoring youthful contours.
• EndoGel Scar Therapy: Minimizes the appearance of scars, reducing discomfort and improving skin texture.

Join the Pacira Revolution

Visit our website today and discover how Pacira BioSciences can revolutionize your practice and improve patient care. Our team of experts is dedicated to providing you with the latest advancements in pain management and aesthetic medicine.

Experience the transformative power of Pacira BioSciences. Unlock the potential of painless tissue expansion and elevate your practice to new heights. Visit us now.

Main Supplier of Pacira BioSciences

Name: Lonza Ltd.

Website: https://www.lonza.com/

Services Provided:

• Manufacture and supply of bulk drug substance (active pharmaceutical ingredient) for EXparel® (bupivacaine liposome injectable suspension)
• Technical support and quality control services

Additional Information:

• Lonza is a global biopharmaceutical company headquartered in Basel, Switzerland.
• It is a leading provider of contract manufacturing services for the pharmaceutical industry.
• Lonza has been a key partner of Pacira BioSciences since the early development of EXparel®.
• The partnership between Pacira and Lonza has enabled Pacira to commercialize EXparel® and bring its benefits to patients.

Primary Customer Segments of Pacira BioSciences

Pacira BioSciences' primary customer segments are healthcare providers, including physicians and surgeons, and healthcare facilities such as hospitals, surgery centers, and pain clinics. These customers use Pacira's products to improve patient outcomes, reduce opioid use, and enhance practice efficiency.

List of Main Customers (Downstream Companies) of Pacira BioSciences

Pacira BioSciences' main customers include:

• Hospitals: Hospital systems account for a significant portion of Pacira's revenue. Pacira's products are used by hospitals to treat patients undergoing surgery, reducing the need for opioids and improving patient recovery. Notable hospital customers include:
  • Intermountain Healthcare
  • St. Joseph Mercy Ann Arbor
  • Hackensack Meridian Health
• Surgery Centers: Ambulatory surgery centers (ASCs) are another major customer segment for Pacira. Pacira's products are used in ASCs to help patients manage pain following outpatient procedures. Key ASC customers include:
  • Surgery Partners
  • Symbion
  • United Surgical Partners International
• Pain Clinics: Pain management clinics use Pacira's products to treat chronic pain and pain associated with injuries or surgical procedures. Pacira's solutions help reduce pain and improve the quality of life for patients. Major pain clinic customers include:
  • Pain Management Centers of America
  • Relievant Health
  • Comprehensive Pain Management, LLC
• Physicians: Individual physicians are also important customers of Pacira BioSciences. Surgeons use Pacira's products to enhance patient outcomes and reduce the risk of complications. Other physicians, such as pain specialists and anesthesiologists, prescribe Pacira's products to manage pain and improve patient recovery.
• Other Healthcare Providers: Pacira BioSciences also serves other healthcare providers, including:
  • Dentists
  • Oral surgeons
  • Podiatrists
  • Chiropractors

Websites of Main Customers

• Intermountain Healthcare
• St. Joseph Mercy Ann Arbor
• Hackensack Meridian Health
• Surgery Partners
• Symbion
• United Surgical Partners International
• Pain Management Centers of America
• Relievant Health
• Comprehensive Pain Management, LLC

Key Revenue Stream: Pharmaceutical Sales

Estimated Annual Revenue: $1.0 billion (2022)

Pacira BioSciences primarily generates revenue through the sales of its pharmaceutical products, specifically its non-opioid pain management portfolio. The company's flagship product is EXPAREL (bupivacaine liposome injectable suspension), a long-acting local anesthetic indicated for post-surgical pain management. Other key products in the portfolio include:

• ICF (icatibant injection): A bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema (HAE).
• ZYNRELEF (naloxegol oxalate): A peripherally acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC).

Product Revenue Breakdown (2022):

• EXPAREL: $773.5 million
• ICF: $160.4 million
• ZYNRELEF: $66.2 million

Other Revenue Streams

In addition to pharmaceutical sales, Pacira BioSciences also has other revenue streams:

• Licensing and Collaboration Agreements: The company enters into agreements with other pharmaceutical companies to develop, manufacture, and commercialize its products. This can generate upfront payments, royalties, and milestone payments.
• Research and Development Funding: Pacira BioSciences receives funding from government agencies and other sources to support its research and development efforts.
• Interest Income: The company earns interest income from its investments.

However, these revenue streams are relatively minor compared to pharmaceutical sales, which account for the vast majority of Pacira BioSciences' revenue.

Key Partners of Pacira BioSciences

Pacira BioSciences, Inc. is a specialty pharmaceutical company that develops and commercializes non-opioid pain management products. The company's key partners play a crucial role in supporting its research and development, manufacturing, and commercialization efforts.

Name | Website | Role ---|---|--- Bayer | https://www.bayer.com/en | Commercialization Partner - Collaborated to commercialize EXPAREL® in Europe, Canada, and Australia. Hikma Pharmaceuticals PLC | https://www.hikm.com/ | Manufacturing Partner - Agreement to manufacture and supply EXPAREL® in Europe and other markets. Mallinckrodt Pharmaceuticals | https://www.mallinckrodt.com/ | Manufacturing Partner - Agreement to manufacture and supply DepoFoam® in the United States. Pharmalink | https://www.pharmalink.com/ | Manufacturing Partner - Agreement to manufacture and fill pre-filled syringes of EXPAREL® in the United States. Recipharm | https://www.recipharm.com/ | Manufacturing Partner - Agreement to manufacture and supply iovera° in Europe.

Additional Information:

• Bayer is a global healthcare company that provides innovative therapies in various therapeutic areas. Its partnership with Pacira BioSciences allows the company to expand the reach of EXPAREL® in key international markets.
• Hikma Pharmaceuticals PLC is a multinational pharmaceutical company with a strong presence in the generics and branded pharmaceuticals markets. Its manufacturing expertise supports the production of EXPAREL® in Europe and other regions.
• Mallinckrodt Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing therapies for severe or life-threatening conditions. Its manufacturing capabilities ensure a reliable supply of DepoFoam® in the United States.
• Pharmalink is a leading provider of contract development and manufacturing services for the pharmaceutical industry. Its partnership with Pacira BioSciences supports the production of pre-filled syringes of EXPAREL® in the United States.
• Recipharm is a contract development and manufacturing organization (CDMO) that provides a wide range of services to the pharmaceutical industry. Its manufacturing expertise contributes to the production of iovera° in Europe.

Key Cost Structure

Research and Development (R&D)

R&D expenses are the largest cost component for Pacira BioSciences. The company invests heavily in research and development to discover, develop, and commercialize new products. This includes costs for clinical trials, preclinical studies, and regulatory submissions. In 2020, Pacira BioSciences spent $96.3 million on R&D, representing 33% of total operating expenses.

Sales and Marketing (S&M)

S&M expenses are the second largest cost component for Pacira BioSciences. The company spends heavily on sales and marketing to promote its products and generate demand. This includes costs for sales representatives, marketing campaigns, and advertising. In 2020, Pacira BioSciences spent $81.1 million on S&M, representing 28% of total operating expenses.

General and Administrative (G&A)

G&A expenses are the third largest cost component for Pacira BioSciences. These expenses include costs for corporate overhead, legal fees, accounting fees, and other administrative functions. In 2020, Pacira BioSciences spent $39.4 million on G&A, representing 14% of total operating expenses.

Cost of Goods Sold (COGS)

COGS are the costs incurred to produce and sell Pacira BioSciences' products. This includes costs for raw materials, manufacturing, and packaging. In 2020, Pacira BioSciences spent $27.1 million on COGS, representing 9% of total operating expenses.

Estimated Annual Cost

The estimated annual cost of Pacira BioSciences' key cost structure is as follows:

• R&D: $96.3 million
• S&M: $81.1 million
• G&A: $39.4 million
• COGS: $27.1 million

Total: $243.9 million

It is important to note that these costs are estimates and may vary depending on factors such as the company's product pipeline, regulatory environment, and competitive landscape.

Sales Channels

Pacira BioSciences' primary sales channels include:

• Hospitals and Health Systems: Pacira's products are sold to hospitals and health systems through its direct sales force and distribution partners. Approximately 80% of Pacira's revenue is derived from this channel.
• Surgical Centers and Clinics: Pacira also sells its products to surgical centers and clinics through its direct sales force and distribution partners. This channel accounts for approximately 15% of Pacira's revenue.
• Other: Pacira also generates a small amount of revenue from other channels, such as government agencies and group purchasing organizations.

Estimated Annual Sales

Pacira BioSciences' estimated annual sales are as follows:

• 2022: $531.8 million
• 2023: $683.4 million (estimated)

Factors Affecting Sales Channels

The following factors can impact Pacira BioSciences' sales channels:

• Competition: Pacira faces competition from other pharmaceutical companies that offer similar products, such as Johnson & Johnson and AstraZeneca.
• Reimbursement: Pacira's products are covered by Medicare and most commercial insurance plans. However, reimbursement policies can vary, which can impact sales.
• Product Development: Pacira is actively developing new products, which can create new opportunities for growth.
• Regulatory Environment: The regulatory environment for pharmaceutical products is complex and can impact sales.
• Market Trends: Changes in the healthcare industry, such as the increasing use of outpatient surgery, can affect the demand for Pacira's products.

Sales Strategy

Pacira BioSciences' sales strategy involves the following key elements:

• Targeted Marketing: Pacira targets its marketing efforts to specific healthcare professionals who are likely to prescribe its products.
• Strong Sales Force: Pacira has a dedicated sales force that provides education and support to healthcare providers.
• Strategic Partnerships: Pacira has established partnerships with key healthcare organizations to increase its reach and market share.
• Product Innovation: Pacira is committed to developing innovative new products that meet the needs of healthcare providers and patients.

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a biopharmaceutical company focused on developing and commercializing non-opioid pain management products. The company's pipeline includes EXparel® (bupivacaine liposome injectable suspension), a non-opioid local anesthetic injected into the surgical site to provide extended pain relief.

Pacira BioSciences' target customer segments include:

• Hospitals and surgery centers: Pacira BioSciences sells EXparel directly to hospitals and surgery centers. The company's sales force targets surgeons and other healthcare professionals who are involved in pain management decisions.
• Physicians: Pacira BioSciences also sells EXparel to physicians who practice in pain management clinics and other settings. The company's sales force targets physicians who are looking for non-opioid pain management options for their patients.
• Patients: Pacira BioSciences' ultimate customers are patients who are experiencing pain. The company's marketing efforts are targeted at patients who are looking for non-opioid pain management options.

Pacira BioSciences' estimated annual sales:

• 2020: $600 million
• 2021: $700 million
• 2022: $800 million

The company's sales are expected to continue to grow in the future as EXparel becomes more widely adopted by hospitals, surgery centers, physicians, and patients.

In addition to the above, Pacira BioSciences is also developing other non-opioid pain management products. These products include:

• PAC103: A local anesthetic that is injected into the epidural space to provide pain relief after surgery.
• PAC203: A local anesthetic that is injected into the joint to provide pain relief from osteoarthritis.

These products are still in the early stages of development, but they have the potential to further expand Pacira BioSciences' target customer segments and annual sales.

Pacira BioSciences' Value Proposition

Pacira BioSciences is a specialty pharmaceutical company focused on the development and commercialization of non-opioid pain management and regenerative health solutions. The company's core value proposition revolves around providing innovative and effective treatments for patients suffering from acute and chronic pain.

Key Value Drivers:

• Non-Opioid Pain Management: Pacira's flagship product, EXPAREL, is a long-acting local anesthetic that provides extended pain relief for up to 72 hours. EXPAREL is a non-opioid alternative to traditional opioids, offering potential benefits such as reduced risk of addiction, respiratory depression, and other opioid-related side effects.
• Targeted Drug Delivery: EXPAREL is delivered using Pacira's proprietary DEPOFOAM technology, a biodegradable, multi-vesicular liposome formulation. DEPOFOAM allows for controlled and prolonged release of the drug, providing sustained pain relief for extended periods.
• Regenerative Health Solutions: Pacira is also developing a portfolio of regenerative health solutions, including products for cartilage repair and wound healing. These products aim to restore or enhance tissue function and reduce pain associated with various conditions.
• Patient-Centric Approach: Pacira places a strong emphasis on patient needs and outcomes. The company conducts extensive research and clinical trials to ensure the safety and efficacy of its products. Pacira also provides educational programs and resources to support patients and healthcare providers in managing pain effectively.
• Strong Intellectual Property Portfolio: Pacira has a robust intellectual property portfolio, including patents protecting its core technologies and products. This portfolio provides the company with a competitive advantage and ensures exclusive rights to its proprietary formulations and delivery systems.

Target Market and Market Position:

Pacira's target market includes patients suffering from acute and chronic pain, as well as healthcare providers and institutions involved in pain management. The company's products are used in a variety of settings, including hospitals, surgery centers, and pain clinics. Pacira has established a leadership position in the non-opioid pain management market, particularly for extended-release local anesthetics.

Competitive Advantage and Differentiation:

Pacira differentiates itself from competitors through its:

• Strong patent protection and proprietary drug delivery technology
• Focus on non-opioid pain management solutions
• Patient-centric approach and commitment to clinical research
• Experienced management team with expertise in pain management and drug development

Conclusion:

Pacira BioSciences' value proposition centers around providing innovative and effective non-opioid pain management and regenerative health solutions. The company's commitment to research, patient outcomes, and proprietary drug delivery systems positions it as a leader in the non-opioid pain management market and a promising player in the field of regenerative medicine.

Pacira BioSciences Company Risk Factors

Business Risk Factors

• Dependence on Exparel: Exparel is Pacira BioSciences' primary product and generates a significant portion of its revenue. Any changes in demand for or reimbursement for Exparel could materially affect the company's financial performance.
• Competition: Pacira BioSciences faces competition from other pharmaceutical companies, as well as from generic manufacturers. Competition could limit the company's ability to increase market share and maintain profitability.
• Product Development Risks: Pacira BioSciences is involved in the development of new products. The development of new products is expensive and time-consuming, and there is no guarantee that the company will be successful in bringing new products to market.
• Manufacturing Risks: Pacira BioSciences relies on third-party manufacturers to produce its products. Any disruptions to the manufacturing process could delay the launch of new products or interrupt the supply of existing products.
• Regulatory Risks: Pacira BioSciences is subject to regulation by the U.S. Food and Drug Administration (FDA) and other regulatory agencies. Changes in regulatory requirements could affect the company's ability to market and sell its products.

Financial Risk Factors

• High Debt: Pacira BioSciences has a high level of debt relative to its equity. This debt could limit the company's ability to make acquisitions or invest in new products.
• Unfavorable Interest Rate Changes: Pacira BioSciences' debt is subject to interest rate fluctuations. Increases in interest rates could increase the company's interest expense and reduce its profitability.
• Fluctuating Foreign Currency Exchange Rates: Pacira BioSciences has international operations. Fluctuations in foreign currency exchange rates could affect the company's financial results.

Other Risk Factors

• Intellectual Property Risks: Pacira BioSciences' products are protected by patents. However, there is no guarantee that the company will be able to successfully defend its patents against challenges from competitors.
• Legal and Regulatory Risks: Pacira BioSciences is subject to lawsuits and other legal proceedings. Unfavorable outcomes in these proceedings could damage the company's reputation and financial performance.
• Environmental Risks: Pacira BioSciences' operations could be affected by environmental regulations and climate change. The company could be required to make significant investments to comply with environmental regulations, which could reduce its profitability.